Reassuring results on cardiovascular safety of DPP-4 inhibitors
Pediatric News ,
AT ICE/ENDO 2014 CHICAGO – Treatment with a dipeptidyl peptidase-4 inhibitor in real-world community practice doesn’t increase…
AT ICE/ENDO 2014 CHICAGO – Treatment with a dipeptidyl peptidase-4 inhibitor in real-world community practice doesn’t increase…
AT THE AHA SCIENTIFIC SESSIONS DALLAS – The glycemia-lowering drug saxagliptin led to a "real" excess of hospitalizations for…
SAN DIEGO – Preventive cardiovascular medicine will get “a big boost” from ongoing major randomized controlled trials due to…
SILVER SPRING, MD.– Results of a large postmarketing study evaluating the cardiovascular safety of saxagliptin in a high-risk…